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INDUCTION OF LABOUR DEFINITION
Induction of labour (IOL) is the process of starting labour artificially, as opposed to waiting for labour to start naturally by itself.
BACKGROUND
For induction of labour to be considered and to be offered, there must be evidence that such an intervention carries benefits for the mother and/or her baby and this requires careful consideration of the clinical evidence in discussion with the woman. In all cases, there is a clear need for the provision of information to allow women to make a fully informed choice.
It is also imperative that the most accurate information is obtained concerning the gestational age of the pregnancy. In most instances, there will be reliable menstrual data supported by evidence from an ultrasound (USS) examination made in the early weeks of pregnancy.
The LMP date should agree with the USS dates within the following margin of error < 12 weeks +/-5 days 12-20 weeks +/-7 days 1 Otherwise the USS date should be taken as the women's agreed estimated due date (EDD).
If, after discussion of the relevant issues, the woman chooses to decline the offer of IOL, further discussion is required regarding the measures needed for ongoing monitoring of the pregnancy (see section 1.4).
It is also important to inform the woman that induction of labour is not always successful and she should be given information as to the likely management should the intervention prove unsuccessful (see section 5.2).
INDICATIONS
IOL is indicated when the maternal and/or fetal risks of continuing pregnancy outweigh the risks of IOL and birth. Specific circumstances are considered in section 2.
CONTRAINDICATIONS
Contraindications to IOL are consistent with vaginal birth contraindications. Specific circumstances where IOL is to be performed with caution are described in sections 5.5-5.8
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ATTENDANCE BY LEAD MATERNITY CARER
When there is a decision between the secondary maternity team, the lead maternity carer (LMC) and the woman for the LMC to remain involved in the midwifery care of a woman having an induction, Birthing Suite will:
 Be responsible for negotiating with the LMC and the woman, a clear written management plan for the initiation of the induction and the ongoing management of the induction.
82
 Assist the LMC to provide care according to the clear written management plan for the induction and the wishes of the woman, until such time as labour is established and the LMC is in attendance 82 or until the woman wants continuous support from her LMC. 83  Provide the LMC reasonable notice of the need to be available to attend to the woman 82 including if the woman wants continuous support from her LMC. 83 The care plan is woman centred and sets out specific midwifery decisions and actions in an effort to meet the woman's goals and expectations. 83 The midwife updates the CCO with the care plan in order for the birthing suite workload to be planned.
MEMBRANE SWEEPING
Membrane sweeping refers to the digital separation of the fetal membranes from the lower uterine segment during vaginal examination. This movement helps to separate the cervix from the membranes and helps to stimulate the release of prostaglandins, encouraging spontaneous onset of labour. Is used to reduce the need for formal IOL by encouraging spontaneous labour.
Risk/Benefit
From 38-40 weeks onwards, significantly reduced pregnancies beyond 41 weeks. 8 Repeated membrane sweeping has been found to decrease the proportion of post term pregnancies. 9 Reduced need for formal IOL 10 , particularly in multiparous women. 9 Limited data on risk in Group B Streptococcus (GBS) carriers. 11 No evidence of increased risk of maternal or neonatal infection. 8 Associated with discomfort 8, 9 , vaginal bleeding and irregular contractions. 8 Most women would choose membrane sweeping again.
9

Recommendations
Consider offering membrane sweep at 39-40 weeks, especially to low risk multiparous women.
12
Advise of the benefits of repeated membrane sweeping.
If the cervix is closed and membrane sweeping is not possible, cervical massage in the vaginal fornices may achieve similar effect.
13
SPECIFIC CIRCUMSTANCES
Considerations for specific IOL indications are outlined in the following sections:
2.1 PROLONGED PREGNANCY 
Recommendations
For women with uncomplicated pregnancies, IOL is offered at agreed EDD+10, or as soon as practicable after that date. 13, 15 From 42 weeks, women who decline IOL are offered increased antenatal monitoring consisting of twice weekly CTG and ultrasound estimation of amniotic fluid index and umbilical arterial Doppler ultrasound 6 . However, there is no evidence that this reduces the risk of stillbirth. Exact timing of IOL depends on the women's preferences and local circumstances.
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Recommendations
Gestation between 34 +0 -36
+6
Decision should be made by the obstetric SMO, based on discussion with the woman and her partner and on the availability of NICU facilities. Gestation less than 34 weeks IOL is not recommended unless there are additional obstetric or fetal indications.
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Guideline
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21
Rates of admission to NICU and need for post-natal antibiotics are reduced.
Recommendations Vaginal examination (VE) is contraindicated in the absence of contractions. If required, a sterile speculum examination is the examination of choice.
Women should be offered IOL at 24 hours post PROM, or as soon as practicable after that time.
Women should be offered intrapartum IV antibiotics to reduce the risk of GBS infection, to be commenced at the start of the augmentation process. If meconium stained liquor or known GBS positive status are present IOL should be expedited. Dinoprostone can be used for cervical ripening. It is recommended to commence oxytocin at 12 hours however if the cervix remains unfavourable consider leaving the Dinoprostone insitu for a further 12 hours. Dinoprostone should not be continued for longer than 24 hours. Women should be checked by the midwife every 1-2 hours between the 6 hourly CTGs (and not rely on maternal notification of change) due to a risk of rapid reaction to dinoprostone (Cervidil). Removal of dinoprostone MUST be documented in the clinical notes to ensure there is evidence that the pessary has been observed to be removed and has not been retained.
Guideline
GLM0043 Pre-Labour Rupture of Membranes at Term GLM0032 Group B Strep Management and Prophylactic Antibiotics
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PREVIOUS CAESAREAN SECTION TABLE 5 Previous caesarean section
Risk/Benefit
There is a 2-3 fold increased risk (overall risk of 1.5%) of uterine rupture and around a 1.5 fold increased risk (0.75%) of caesarean section in induced and/or augmented trial of labour compared with spontaneous labour. 22 The current evidence is inconclusive regarding risk of rupture with IOL with prostaglandins vs. non-prostaglandin methods. The National Institute of Child Health and Development (NICHD) 23 study of prostaglandin induction compared with non-prostaglandin induction incurred a non-significantly higher risk of uterine rupture of 1.4% versus 0.9%, whereas in an analysis of nationally collected data from Scotland 24 , prostaglandin induction compared with nonprostaglandin induction was associated with a statistically significantly higher uterine rupture risk of 0.9% versus 0.3%.
Recommendations
The additional risks in induced Trial of Labour (TOL) mean that:  although IOL is not contraindicated it should only be preceded by detailed obstetric assessment, maternal counselling and a documented plan completed by the obstetric SMO.
25
Guideline GLM0017 Birth After Previous Caesarean Section 2.5 OBSTETRIC CHOLESTASIS   TABLE 6 Obstetric cholestasis
Risk/Benefit
There remains insufficient data to support or refute the popular practice of 'early' (37 weeks of gestation) induction of labour aimed at reducing late stillbirth. The timing and risks of birth should be discussed with the woman and her LMC on an individualised basis 26 . Obstetric cholestasis is associated with increased risk of 26 :  Premature birth is increased, both spontaneous and iatrogenic  Current stillbirth rate for treated obstetric cholestasis is comparable to that in the general population. The risk of stillbirth in 'untreated' obstetric cholestasis remains unclear  Evidence of increased risk of meconium stained liquor, caesarean section or PPH is inconclusive
Timing of birth decisions should not be based on the degree of abnormality of biochemical tests alone, as current data are not robust enough to demonstrate or exclude a correlation between maternal levels of liver enzymes or bile salts and intrauterine death.
IOL can be offered to women at or after 38 weeks of gestation or earlier in the presence of worsening biochemical or clinical evidence prior to 38 weeks gestation.
Women should be also informed of the increased risk of maternal morbidity WCH/GLM0035 (23864)
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Recommendations
Until quality evidence is available, or the introduction of the New Zealand National Guideline at CDHB: Pre-existing Type 1 and 2 DM Offer IOL at 38 weeks (or beyond) if control remains optimal with no evidence of fetal macrosomia or other pregnancy concern. The decision to offer IOL before this time should be made at an Obstetric SMO level in association with the Obstetric physician.
GDM on Insulin and/or Metformin
Offer IOL at 39 weeks or beyond if control remains optimal with no evidence of fetal macrosomia or other pregnancy concern.
Offer IOL from 38 weeks in the setting of sub-optimal control, fetal macrosomia or any other signs of fetal compromise.
GDM on diet and exercise alone
Offer IOL at 40 weeks or beyond, dependent on individual circumstances. The only cure for pre-eclampsia is birth. 8, 13, 36 In pregnancies < 34 weeks there is a clear association between preterm birth and increased neonatal morbidity with no apparent decrease in maternal morbidity.
In severe preeclampsia there is a lack of evidence to support expectant management beyond 34 weeks. IOL is associated with high rates of intrapartum caesarean section.
In mild preeclampsia there is clear evidence of clinical benefit of immediate, ie within 24 hours, birth after 36 weeks gestation.
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In non-severe hypertension:  IOL reduced the risk of progression to more severe maternal disease to 31% in IOL group compared to 44% in those expectantly managed: 38 No differences in composite neonatal outcome.  No differences in mode of birth.
Recommendations
The decision regarding birth should be made once the woman is stable, appropriate senior personnel are present and a full antenatal steroid course has been completed if clinically appropriate. Retrospective studies demonstrate:  Perinatal mortality rate is lowest for birth at 37 weeks gestation.
42
 An increase in stillbirth, particularly beyond 38 weeks.
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 An underpowered randomised controlled trial comparing expectant management with IOL at 37 weeks showed no statistical difference in rates of CS, CS for fetal distress or perinatal death. 44 In uncomplicated twin pregnancy there is insufficient data to support the practice of planned birth from 37 weeks. 41 The main determinant of risk in a multiple pregnancy is chorionicity and this may influence decisions regarding the timing of birth in individual cases.
Recommendations
Taking into account individual circumstances, offer IOL after 38+0 weeks. 43 
INTRAUTERINE GROWTH RESTRICTION (IUGR) TABLE 10
Intrauterine growth restriction (IUGR)
Risk/Benefit
Defined as occurring when a fetus has failed to reach its growth potential and may be associated with serious intrapartum and neonatal complications. 45, 46 It results mostly from chronic placental insufficiency and these fetuses are identified by the presence of growth below the 10th customised centile which is usually associated with umbilical artery Doppler abnormalities and reduced amniotic fluid volume. 45, 47 The optimal timing of birth in a preterm fetus with growth restriction is controversial, requiring careful consideration of the severity of the growth restriction and its impact on fetal wellbeing balanced against the gestational age.
Recommendations
 All decisions for, and timing of birth, must be made in consultation with both the Obstetric and Neonatal SMO. 
Risk/Benefit
Defined as an estimated fetal weight (EFW) less than the 10 th customised centile (using GROW software accessed at www.gestation.net).
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 At present there is no effective intervention to alter the course of SGA except birth. Timing of birth is therefore a critical issue in order to balance the risks of prematurity against those of continued intrauterine stay; death and organ damage due to inadequate tissue perfusion 49. Gestational age is a critical determinant in decision making. Various tools exist to predict survival in very preterm births, such as the prematurity risk evaluation measure (PREM) score.
50
 The consensus view from the recent Disproportionate Intrauterine Growth Intervention Study at Term (DIGITAT) is that the optimum time for induction in SGA pregnancies is at around 38 weeks' -this was associated with the lowest perinatal morbidity. 83, 84 This recommendation also is in keeping with findings from population-based studies which suggest that delivery of SGA infants at 38 weeks of gestation may be associated with lower perinatal mortality compared with later delivery. 85 Data from DIGITAT also showed that a policy of induction of labour in SGA babies at term (greater than 37 weeks') was not associated with increased risk of Caesarean section. Method of induction of labour  The optimum mode of induction of labour for these infants may be with a Foley catheter, as this reduces the risk of hyper stimulation with fetal heart changes 86 which the SGA fetus may not tolerate as well as an appropriatelygrown fetus.
For all pregnancies complicated by abnormal dopplers, refer to above section: Intrauterine growth restriction.
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IN-VITRO FERTILISATION (IVF) PREGNANCY TABLE 13 In-vitro fertilisation (IVF) pregnancy
Risk/Benefit
Pooled results from studies suggest there is nearly a 70% increased risk in perinatal death for IVF singletons compared with natural conceptions 55 . However, out of all assisted reproductive techniques, only women who conceived with IVF had a statistically significant four-fold increased risk of stillbirth compared with fertile women. 56 This would suggest that the increased risk of stillbirth is associated with treatment-related factors to a greater degree than infertility/subfertility itself.
Recommendations
Offer IOL to women with IVF pregnancies at 40 weeks BUT not following other assisted reproduction techniques (ART). 
RECURRENT ANTEPARTUM HAEMORRHAGE (APH)
Risk/Benefit
There are few high quality clinical trials to guide management of APH. The optimum timing of birth for women presenting with unexplained recurrent APH and no maternal and/or fetal compromise has therefore not been established.
Recommendations
 If there is no evidence of maternal and/ or fetal compromise expectant management is an option with increased fetal surveillance.
 Where there is evidence of maternal and/or fetal compromise a SMO must be consulted to determine the timing and mode of birth in consultation with the woman and her LMC.
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Risk/Benefit
Defined as estimated fetal weigh more than the 90 th centile on customised charting. Literature review of 20 studies reported that the probability of detecting a macrosomic fetus in an uncomplicated pregnancy is variable, ranging from 15% to 79% with sonographic estimates of birth weight. 57 A systematic review (n=3751 women) compared expectant management with IOL in cases of suspected fetal macrosomia 58 reported no significant differences in maternal or fetal outcomes. Summary statistics for nine observational studies suggested that, compared with IOL, woman with suspected fetal macrosomia who experienced spontaneous onset of labour had a lower incidence of caesarean birth (OR 0.39, 95% CI 0.30 to 0.50).
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Recommendations
Suspected fetal macrosomia in the absence of diabetes is not an indication for IOL.
PELVIC ARTHROPATHY (SPD) TABLE 16 Pelvic arthropathy (SPD)
Risk/Benefit Pelvic arthropathy of pregnancy or Symphysis Pubis Dysfunction (SPD) is a condition described in terms of symptoms and signs. These occur due to physiological relaxation of the pelvic ligaments and increasing joint mobility in pregnancy. There appears to be no correlation between levels of discomfort and disability and degree of relaxation. Treatment is generally conservative and birth is curative in the majority by 6 months postpartum.
Recommendations
 Women should be counselled that there is a significant delay between birth and resolution of pain.
 SPD is not an indication for IOL.
Induction of Labour
Risk/Benefit
Precipitate labour is defined as expulsion of the fetus within less than 3 hours of commencement of contractions 60 and has an incidence of about 2% in women with spontaneous, non-augmented labours. 61 No studies were identified that compared induction of labour with no induction of labour in women with a history of precipitate labour, and thus there is no evidence to suggest that inducing labour can prevent precipitate labour.
Recommendations
 Induction of labour to avoid a birth unattended by healthcare professionals should not be offered.  History of precipitate labour is not an acceptable indication for IOL.
MATERNAL REQUEST TABLE 18
Maternal request
Risk/Benefit
Induction of labour at term without medical indication continues to be widely criticised on the basis that it is an unnecessary intervention and it carries risks. There is no direct evidence to determine the effects of induction of labour on maternal request and evidence on induction of labour at 37-40 completed weeks without a medical indication is also limited. Meta-analysis (n=1300 women) of available trials 62 found no significant difference in perinatal death with expectant versus IOL groups as above, however the induction group was significantly less likely to have caesarean birth (RR 0.58 95% CI 0.34 to 0.99), but more likely to require assisted vaginal birth (RR 1.7, 95% CI 1.23 to 2.39).
Recommendations
 IOL should not be offered on maternal request alone.  Maternal request is not an indication for IOL.
PRE INDUCTION OF LABOUR ASSESSMENT
Complete the following:  Review of maternal history.  Confirmation of gestation.  Perform baseline temperature, pulse and blood pressure measurements.  Perform urinalysis if the woman has diabetes, hypertension or if there has been previous proteinuria.  For women with pre-eclampsia, other medical conditions and other medical complications of pregnancy, ensure that blood is taken on day of IOL and results are available.  Abdominal palpation to confirm presentation and engagement.  Perform a baseline CTG for at least 30 minutes AND until the CTG is normal. If the CTG is ABNORMAL the on-call obstetric team must be consulted.  Where the presenting part is found not to be cephalic either on abdominal palpation or vaginal examination, the obstetric team must be consulted for further assessment. 
CERVICAL ASSESSMENT
The Bishop score is used to assess the cervix. Each feature is scored and the scores are then summed.
The state of the cervix is one of the most important predictors of successful IOL. 63 The cervix is unfavourable if the score is 6 or less. 63 
TABLE 19
Bishop score label Maternity Guidelines
METHODS OF INDUCTION OF LABOUR
WOMEN'S HEALTH SERVICE Christchurch Women's Hospital
There is potential provision to allow two 'low risk' IOLs at a weekend. If IOL is to take place over the weekend, the decision is made in consultation with the CCO, Obstetric SMO on call, LMC and the woman.
Once a date has been booked, the woman is admitted to Birthing Suite at prearranged time of either 0730 or 0800 hrs. Women admitted for induction of labour require a full antenatal assessment and normal EFM prior to the chosen procedure (see section 4).
'UNSUCCESSFUL' IOL
Defined as the inability to perform an ARM after maximal dose of dinoprostone achieved OR 24 hours post Foley's catheter insertion.
In all cases of 'unsuccessful' IOL, the team should re-evaluate the clinical situation and re-affirm that the clinical indication for IOL still exists.
If the decision is made that birth is still required then the following are options for management.
 Rest day
The woman is given a 24 hour 'rest period' in which time she may go into spontaneous labour. Failing that, then the induction regime can be restarted.
 Alternative method induction
For those women who have had an unsuccessful trial of dinoprostone sustained release pessary, a Foley's catheter induction may be offered.
For those women who have an unsuccessful trial of Foley's IOL, a trial of dinoprostone may be appropriate, assuming there are no contraindications to this i.e. previous caesarean section (see section 2.4).
 Caesarean section
For some women it may be more appropriate to discuss the option of caesarean section including the potential risks and complications of surgery and impact on future pregnancies.
UTERINE HYPERSTIMULATION
Uterine hyperstimulation occurs in 1 -5% of IOLs and may present as tachysystole (> 5 contractions in 10 minutes) or hypertonus (contractions lasting > 2 minutes), with or without changes in the fetal heart rate pattern. 
Tocolysis
Acute tocolysis may be achieved as per CWH tocolysis protocol by using: 65, 66 Ruptured Membranes 66 Oxytocin administration 64, 65, 66 Cardiovascular disease 66 Raised intraocular pressure, glaucoma 66 Unexplained vaginal discharge and/or uterine bleeding during current pregnancy 64, 65, 66 Epilepsy 66
Risk/Benefit
Nausea, vomiting and diarrhoea may occur soon after insertion. 66 Increased risk of hyperstimulation with or without FHR abnormality in approximately 4% of women. 67 Incidence of CS in not increased. 67 The risk of hyperstimulation is higher with the pessary than with the gel (4.5% vs. 2.4%). 68 Risk of hyperstimulation is higher if oxytocin is also used.
69
Dosage
See Table 20 for flow chart.
Administration
Perform EFM to confirm fetal wellbeing. Undertake a vaginal examination (use water soluble lubricants -not obstetric cream) and calculate the bishop score. (see table 21 ) Prior to insertion, encourage voiding. Dinoprostone pessary is inserted into the posterior fornix transversely.
Insertion
Holding Dinoprostone insert between the index and middle fingers of the examining hand, insert high into vagina towards the vaginal fornix (use only small amounts water soluble lubricants) 2. Positioning Index and middle fingers should now be twisted a quarter turn clockwise, pushing the Dinoprostone insert higher up, behind the posterior fornix and turning it through 90° so that it lies transversely in the posterior fornix.
Induction of Labour
After positioning
Carefully withdraw the fingers leaving the Dinoprostone inserted in the position shown above. After insertion recommence CTG and ensure that the woman remains recumbent for 30-40 minutes. Allow sufficient tape to remain outside the vagina to permit easy retrieval.
Removal
To stop prostaglandin E2 release, gently pull the retrieval tape and remove the Dinoprostone insert. Document removal in the woman's clinical record.
Post-insertion monitoring
Recommence EFM immediately after administration of dinoprostone. EFM must be performed for at least 30 minutes AND until the EFM is normal. If the woman is low risk, lives locally, observations are normal and EFM normal, she is able to go home one hour after insertion of dinoprostone. A plan must be discussed and documented outlining when to contact LMC and to return to the hospital. If the woman's location means she is unable to return home, alternatives are discussed, with the option to remain an inpatient if no suitable alternatives can be found. Perform EFM at 12 hours post-insertion, or before if the clinical situation dictates. If the woman and/or baby are high risk plan to repeat EFM in 6 hours or before as the clinical situation dictates.
Assessment of progress
If contractions do not commence, reassess the Bishop score 24 hours post dinoprostone pessary insertion.
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Ongoing management
The core midwifery staff (in association with the obstetric team) is responsible for initiating the IOL; however the LMC may do this if they choose to. Clear communication and negotiation must take place between the CCO and the LMC.
Induction of Labour
Removal of dinoprostone pessary
The dinoprostone pessary (Cervidil) is a foreign body, being an object originating outside the body. Removal of the pessary (at the appropriate time as per IOL guideline) and any variance MUST be documented in the woman's clinical record. The obstetric team must be consulted and an SMO involved in the event that the pessary cannot be located for removal or there is any doubt as to whether the pessary has been removed or not. The pessary is not radio opaque and therefore not x ray detectable, so thorough examination will be required in the event that there is concern that the pessary has been retained.
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Consideration
Clinical practice point
Monitoring
Provide one-to-one midwifery care. Ensure dinoprostone pessary is removed 30 minutes prior to commencement of oxytocin. Use continuous EFM once oxytocin infusion commenced 69, 72 Titrate dose to achieve 3-4 strong regular contractions in 10 minutes. Assess maternal observations and FHR prior to any increase in the infusion rate. Maternal observations (more frequently if clinically indicated)  Temperature 2 hourly  BP hourly  Pulse hourly  Vaginal loss hourly Maintain fluid balance as water intoxication may result from prolonged infusion 69 (rare with the use of isotonic solutions).
Assess pain relief requirements.
Assessment of progress
Commence the partogram with the start of the oxytocin infusion.
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This document is to be viewed via the CDHB Intranet only. All users must refer to the latest version from the CDHB intranet at all times. Any printed versions, including photocopies, may not reflect the latest version. The aim is to achieve 3 to 4 regular moderate to strong contractions in 10 minutes, lasting 45 to 60 seconds. Palpate uterine contractions every 15-30 minutes. If infusion is ceased for insertion of an epidural, recommence infusion at rate being infused at cessation unless otherwise indicated by uterine activity. If the infusion is stopped, the obstetric team is to be consulted prior to recommencing infusion (with the exception of epidural siting). The infusion is to be recommenced at the previous dose then titrated to achieve a rate of 3-4 regular to strong contractions, lasting 45 to 60 seconds (see section 5.3 regarding hypertonic uterine contractions). Document incremental increases/decreases, in woman's clinical notes and on partogram/CTG. 
Side effects
Cautions
Caution should be exercised where the head is high due to risk of cord prolapse.
13
Risk/Benefit
May shorten length of labour by speeding up contractions. TABLE 26 Transcervical catheter considerations
CONSIDERATION COMMENT
Indications
May be particularly useful where the cervix is unfavourable.
May be used where Dinoprostone has had no effect on cervical ripening. May be considered in women with previous CS or major uterine surgery.
Cautions
Contraindication:
 Low lying placenta 
Risk/Benefit
Low cost and no specific storage or temperature requirements. 76 No evidence of an increased risk of chorioamnionitis or endometritis although data is limited. 76 May be associated with slight vaginal bleeding. In women with a very unfavourable cervix, use seems to reduce unsuccessful IOL when compared to IOL with oxytocin alone.
76
Monitoring
Monitor FHR as appropriate to individual clinical circumstances. Obstetric review occurs 24 hours post insertion, or as required before.
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Unsuccessful IOL
The criteria for unsuccessful IOL are generally not agreed. 13 Recommended care options include: 13  Review the individual clinical circumstances  Assess fetal wellbeing using CTG  Discuss options for care with the woman  If appropriate consider discharging home for 24 hours (the 'rest day') followed by second attempt at IOL  Offer alternate method, eg. further dinoprostone or Foley's catheter  Caesarean section in some instances, after all other options have been explored
Uterine hyper contractility
See section 5.3
Epidural analgesia
Because IOL is the artificial commencement of labour, contractions occur without the release of beta-endorphins which help to reduce a woman's pain perceptions. IOL is reported to be more painful, leading to increased use of spinal/epidural analgesia. 75, 76 The use of analgesia is 3.6 times more likely with IOL than spontaneous labour in nulliparous woman.
Postpartum Haemorrhage (PPH)
In low risk women IOL is associated with a 20% higher risk of PPH and severe PPH, regardless of the method used for IOL. 78 The use of ARM in conjunction with IV oxytocin is associated with more PPH when compared to other methods of IOL.
79
Assisted birth A Cochrane review of 12 trials involving 6227 women IOL was associated with increased rates of instrumental birth, RR 1.1
80
Cord prolapse Is a potential risk at the time of membrane rupture especially with ARM. 13 Is an obstetric emergency. 13 Precautions should include:  Assessment of engagement of the presenting part.  Caution during ARM if the baby's head is high.
Uterine rupture
Uterine rupture is an uncommon event with IOL. 13 Uterine rupture is a life-threatening event for mother and baby. If suspected, prepare for a category one caesarean section, followed by uterine repair or hysterectomy.
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